Suhexiang Pill for Acute Ischemic Stroke: A Registry Study

NCT05833932 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-06-11

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.

Conditions

Interventions

DRUG

Suhexiang Pill

Suhexiang Pill is an approved traditional Chinese patent medicine.

Sponsors & Collaborators

  • Dongzhimen Hospital, Beijing

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05833932 on ClinicalTrials.gov